Jason A SPROWL  SITE

  • Clin Cancer Res. 2021;In press. Regulation of OATP1B1 function by tyrosine kinase-mediated phosphorylation. Hayden E, Chen M, Pasquariello KZ, Gibson AA, Petti JJ, Shen S, Qu J, Ong SS, Chen T, Jin Y, Uddin ME, Huang KM, Paz A, Sparreboom A, Hu S, Sprowl JA. PubMed
  • J Clin Invest. 2020;130:4601-4606 Neuronal uptake transporters contribute to oxaliplatin neurotoxicity in mice. Huang KM, Leblanc AF, Uddin ME, Kim JY, Chen M, Eisenmann ED, Gibson A, Li Y, Hong KW, DiGiacomo D, Xia SH, Alberti P, Chiorazzi A, Housley SN, Cope TC, Sprowl JA, Wang J, Loprinzi CL, Noonan A, Lustberg M, Cavaletti G, Pabla N, Hu S, Sparreboom A. PubMed
  • Clin Pharmacol Ther. 2018;104:799-802. Strategies to reduce Solute Carrier-mediated toxicity. Hu S, Sprowl JA. PubMed
  • Clin Pharmacol Ther. 2018;104:900-915. Disease-associated changes in drug transporters may impact the pharmacokinetics and/or toxicity of drugs: A white paper from the International Transporter Consortium. Evers R, Piquette-Miller M, Polli JW, Russel FGM, Sprowl JA, Tohyama K, Ware JA, de Wildt SN, Xie W, Brouwer KLR; International Transporter Consortium. PubMed
  • J Clin Invest. 2018;128:816-825. OATP1B2 deficiency protects against paclitaxel-induced neurotoxicity. Leblanc AF, Sprowl JA, Alberti P, Chiorazzi A, Arnold WD, Gibson AA, Hong KW, Pioso MS, Chen M, Huang KM, Chodisetty V, Costa O, Florea T, de Bruijn P, Mathijssen RH, Reinbolt RE, Lustberg MB, Sucheston-Campbell LE, Cavaletti G, Sparreboom A, Hu S. PubMed
  • Clin Transl Sci. 2017;10:412-420. Identification of OAT1/OAT3 as contributors to Cisplatin toxicity. Hu S, Leblanc AF, Gibson AA, Hong KW, Kim JY, Janke LJ, Li L, Vasilyeva A, Finkelstein DB, Sprowl JA, Sweet DH, Schlatter E, Ciarimboli G, Schellens J, Baker SD, Pabla N, Sparreboom A. PubMed
  • Nat Commun. 2016;7:10880. A phosphotyrosine switch regulates organic cation transporters. Sprowl JA, Ong SS2, Gibson AA, Hu S, Du G, Lin W, Li L, Bharill S, Ness RA, Stecula A, Offer SM, Diasio RB, Nies AT, Schwab M, Cavaletti G, Schlatter E, Ciarimboli G, Schellens JHM, Isacoff EY, Sali A, Chen T, Baker SD, Sparreboom A, Pabla N. PubMed
  • Proc Natl Acad Sci U S A. 2015;112:5231-6. Mitigation of acute kidney injury by cell-cycle inhibitors that suppress both CDK4/6 and OCT2 functions. Pabla N, Gibson AA, Buege M, Ong SS, Li L, Hu S, Du G, Sprowl JA, Vasilyeva A, Janke LJ, Schlatter E, Chen T, Ciarimboli G, Sparreboom A. PubMed
  • Pharmacogenomics. 2015;16:323-32. Human OCT2 variant c.808G>T confers protection effect against cisplatin-induced ototoxicity. Lanvers-Kaminsky C, Sprowl JA, Malath I, Deuster D, Eveslage M, Schlatter E, Mathijssen RH, Boos J, Jürgens H, Am Zehnhoff-Dinnesen AG, Sparreboom A, Ciarimboli G. PubMed
  • Clin Cancer Res. 2014;20:4026-35. Cisplatin-induced renal injury is independently mediated by OCT2 and p53. Sprowl JA, Lancaster CS, Pabla N, Hermann E, Kosloske AM, Gibson AA, Li L, Zeeh D, Schlatter E, Janke LJ, Ciarimboli G, Sparreboom A. PubMed
  • Drug Metab Dispos. 2014;42:611-22. Uptake carriers and oncology drug safety. Sprowl JA, Sparreboom A. PubMed
  • J Clin Oncol. 2013;31:3442-3. Can erlotinib ameliorate cisplatin-induced toxicities? Sprowl JA, Mathijssen RH, Sparreboom A. PubMed
  • Clin Pharmacol Ther. 2013;94:585-92. Conjunctive therapy of cisplatin with the OCT2 inhibitor cimetidine: influence on antitumor efficacy and systemic clearance. Sprowl JA, van Doorn L, Hu S, van Gerven L, de Bruijn P, Li L, Gibson AA, Mathijssen RH, Sparreboom A. PubMed
  • Proc Natl Acad Sci U S A. 2013;110:11199-204. Oxaliplatin-induced neurotoxicity is dependent on the organic cation transporter OCT2. Sprowl JA, Ciarimboli G, Lancaster CS, Giovinazzo H, Gibson AA, Du G, Janke LJ, Cavaletti G, Shields AF, Sparreboom A. PubMed
  • Mol Cancer Ther. 2013;12:1537-44. Modulation of OATP1B-type transporter function alters cellular uptake and disposition of platinum chemotherapeutics. Lancaster CS, Sprowl JA, Walker AL, Hu S, Gibson AA, Sparreboom A. PubMed
  • Clin Cancer Res. 2013;19:3316-24. CYP3A4*22 genotype and systemic exposure affect paclitaxel-induced neurotoxicity. de Graan AJ, Elens L, Sprowl JA, Sparreboom A, Friberg LE, van der Holt B, de Raaf PJ, de Bruijn P, Engels FK, Eskens FA, Wiemer EA, Verweij J, Mathijssen RH, van Schaik RH. PubMed
  • Clin Pharmacol Ther. 2012;92:531-4. Drug trafficking: recent advances in therapeutics and disease. Sprowl JA, Sparreboom A. PubMed
  • Drug Metab Pharmacokinet. 2013;28:19-27. Polymorphic transporters and platinum pharmacodynamics. Sprowl JA, Ness RA, Sparreboom A. PubMed
  • BMC Cancer. 2012;12:381. Role of aldo-keto reductases and other doxorubicin pharmacokinetic genes in doxorubicin resistance, DNA binding, and subcellular localization. Heibein AD, Guo B, Sprowl JA, Maclean DA, Parissenti AM. PubMed
  • Clin Pharmacol Ther. 2012;91:1022-6. Associations between ABCC2 polymorphisms and cisplatin disposition and efficacy. Sprowl JA, Gregorc V, Lazzari C, Mathijssen RH, Loos WJ, Sparreboom A. PubMed
  • Drug Resist Updat. 2012;15:5-20. Contribution of tumoral and host solute carriers to clinical drug response. Sprowl JA, Mikkelsen TS, Giovinazzo H, Sparreboom A. PubMed
  • Clin Cancer Res. 2012;18:1101-8. Proximal tubular secretion of creatinine by organic cation transporter OCT2 in cancer patients. Ciarimboli G, Lancaster CS, Schlatter E, Franke RM, Sprowl JA, Pavenstädt H, Massmann V, Guckel D, Mathijssen RH, Yang W, Pui CH, Relling MV, Herrmann E, Sparreboom A. PubMed
  • Pharmacogenomics J. 2010;10:489-504. The temporal relationship between ABCB1 promoter hypomethylation, ABCB1 expression and acquisition of drug resistance. Reed K, Hembruff SL, Sprowl JA, Parissenti AM. PubMed

PubMed

Buffalo, United States

SPROWL JASON.jpg

Last update: June 2021